Synergy Pharmaceuticals Completes Phase I Trial of SP-333, a Second

Synergy Pharmaceuticals Completes Phase I Trial of SP-333, a Second

Filed under: drug treatment news 2011

28, 2012 (GLOBE NEWSWIRE) — Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today the successful completion of a Phase I single-ascending-dose clinical trial of SP …
Read more on GlobeNewswire (press release)

 

Canadian Biotech Isn't Dead; Following The Money To Undervalued Equities

Filed under: drug treatment news 2011

The other week, Gilead Sciences (GILD) announced the purchase of YM BioSciences (YMI), an Ontario-based hematology and oncology drug developer, in a deal that valued YMI at $ 510M. More importantly for investors, Gilead's $ 2.95 per share purchase … If …
Read more on Seeking Alpha

 

Drug shortage, cancer recurrence linked

Filed under: drug treatment news 2011

From 2006 to 2011, the number of pharmaceutical drugs considered in short supply by the U.S. Food and Drug Administration jumped from 70 to 250. Some reports show that the drug shortage rate has slowed, but … The trial focused on tailoring radiation …
Read more on San Francisco Chronicle